ObesityTreatment
-
Eli Lilly Isn’t a Bubble — It’s What Dominance Looks Like
Is Eli Lilly overextended? Or are investors still underestimating how big this GLP-1 story can get? Here’s the blunt answer: LLY isn’t cheap. But calling it a bubble is lazy. Let’s look at what’s actually happening. In 2025, Lilly pulled in $65.2B in revenue — up 45% year over year. More than half of that…
-
Wegovy in a Pill Is the Tipping Point for Weight-Loss Drugs
**Wegovy, but make it a pill? Yes — and it changes everything.** For years, the GLP‑1 boom has come with a tiny but mighty catch: needles. Wegovy worked, Ozempic worked, but millions of people quietly noped out at the idea of weekly injections. Now Novo Nordisk has cracked the code. **Wegovy is officially a once‑daily…
You must be logged in to post a comment.